natgillin/translations-raw huggingface dataset:
Draxxin should only be used if pigs are expected to develop the disease within 2-3 days.
Draxxin se uporabi le v primeru, če se pričakuje razvoj bolezni v 2 - 3 dneh.
Do not use the product simultaneously with other macrolides or lincosamides (see section 4.8).
Ne uporabite zdravila skupaj z drugimi makrolidnimi antibiotiki ali linkozamidi (glej poglavje 4. 8) Ne uporabite zdravila pri kravah, namenjenih za proizvodnjo mleka za prehrano ljudi.
Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Ne uporabite zdravila pri brejih kravah ali telicah, namenjenih za proizvodnjo mleka za prehrano ljudi, če je do predvidenega poroda manj kot 2 meseca.
2 4.4 Special warnings for each target species
Posebna opozorila za vsako ciljno živalsko vrsto
4.5 Special precautions for use
2 4. 5 Posebni previdnostni ukrepi
Use of the product should be based on susceptibility testing and take into account offical and local antimicrobial policies.
Zdravilo naj se uporablja le na podlagi preizkusov občutljivosti povzročitelja in ob upoštevanju nacionalnih in področnih pravil uporabe protimikrobnih zdravil.
If accidental eye exposure occurs, flush the eyes immediately with clean water.
V primeru nenamernega stika očesa z zdravilom, prizadeto oko nemudoma sprati s čisto vodo.
If accidental skin exposure occurs, wash the skin immediately with soap and water.
Pri nenamernem stiku kože z zdravilom, je potrebno kožo nemudoma sprati z milom in vodo.
In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.
V primeru nenamernega samo- injiciranja zdravila se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
Subcutaneous administration of DRAXXIN to cattle frequently causes transient pain reactions and local swellings at the injection site that can persist for up to 30 days.
Pri govedu podkožno vbrizgavanje DRAXXINA pogosto povzroči trenutno bolečino in lokalno oteklino na mestu vbrizgavaja, ki lahko vztraja tudi do 30 dni.
No such reactions have been observed in pigs after intramuscular administration.
Teh reakcij pri prašičih po intramuskularnem dajanju ni bilo opaziti.
Pathomorphological injection site reactions are present for approximately 30 days after injection in both species.
Reakcije na mestu vbrizgavanja lahko zaznamo patomorfološko še do 30 dni po vbrizgovanju zdravila pri obeh živalskih vrstah.
4.7 Use during pregnancy, lactation or lay
Uporaba v obdobju brejosti in laktacije
The safety of tulathromycin during pregnancy and lactation has not been established in cattle and pigs.
Varnost uporabe tulatromicina pri govedu in prašičih med brejostjo in laktacijo ni bila preizkušena.
Use only according to the benefit/ risk assessment by the responsible veterinarian.
Uporabite le v skladu z oceno razmerja korist/ tveganje odgovornega veterinarja.
Cattle A single subcutaneous injection of 2.5 mg tulathromycin/ kg body weight (equivalent to 1 ml/ 40 kg body weight).
Govedo Enkratna podkožna aplikacija tulatromicina v odmerku 2, 5 mg/ kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže).
For treatment of cattle over 300 kg body weight, divide the dose so that no more than 7.5 ml are injected at one site.
Za goveda s telesno težo nad 300 kg, je potrebno odmerek razdeliti tako, da na eno mesto aplikacije ne vbrizgamo več kot 7, 5 ml zdravila.
3 Pigs A single intramuscular injection of 2.5 mg tulathromycin/ kg body weight (equivalent to 1 ml/ 40 kg body weight) in the neck.
Prašiči Enkratna intramuskularna aplikacija tulatromicina v odmerku 2, 5 mg/ kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže) na področje vratu.
For treatment of pigs over 80 kg body weight, divide the dose so that no more than 2 ml are injected at one site.
Pri zdravljenju prašičev, ki so težji od 80 kg, je potrebno odmerek razdeliti tako, da na eno mesto aplikacije ne vbrizgamo več kot 2 ml zdravila.
To ensure correct dosage body weight should be determined as accurately as possible to avoid underdosing.
3 Za zagotovitev pravilnega odmerjanja je potrebno čim natančneje določiti telesno težo obolele živali, da zagotovimo zadostno odmerjanje zdravila.
Mild myocardial degeneration has been observed in cattle receiving 5-6X the recommended dose.
Vključevali so tudi nemirnost, stresanje z glavo, brskanje po zemlji in kratkotrajno zmanjšanje zauživanja krme.
Cattle (meat and offal):
Govedo (meso in organi):
Pig (meat and offal):
Prašiči (meso in organi):
33 days
49 dni 33 dni
Not permitted for use in lactating cattle producing milk for human consumption.
Ni dovoljena uporaba pri živalih v laktaciji, katerih mleko je namenjeno prehrani ljudi.
Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Ne uporabite pri brejih kravah in telicah, katerih mleko je namenjeno prehrani ljudi, v obdobju 2 mesecev pred pričakovanim porodom.
Macrolide, ATCvet code:
Farmakoterapevtska skupina: makrolidi, ATCvet oznaka:
They act by stimulating the dissociation of peptidyl-tRNA from the ribosome during the translocation process.
Pri tem pospešujejo disociacijo peptidil- tRNK iz ribosomov med procesom translokacije.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoni, and Haemophilus parasuis the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulatromicin izkazuje in vitro aktivnost proti Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis ter proti Actinobacillus pleuropneumoniae, Pastuerella multocida, Mycoplasma hyopneumoniae in Haemophilus parasuis to je proti patogenim bakterijam, ki so najpogostejši povzročitelji obolenj dihal pri govedu in prašičih.
Increased MIC values have been found in some isolates of Histophilus somni and Actinobacillus pleuropneumoniae.
Pri nekaterih izolatih Histophilus somni in Actinobacyllus pleuropneumoniae so bile ugotovljene povišane MIC vrednosti.
4 Tulathromycin also possesses in vitro activity against Moraxella bovis, the bacterial pathogen most commonly associated with infectious bovine keratoconjunctivitis (IBK).
Tulatromicin izkazuje tudi in vitro aktivnost proti Moraxella bovis patogeni bakteriji, ki je najpogostejša povzročiteljica infekcioznega govejega keratokonjuktivitisa.
5.2 Pharmacokinetic particulars
4 5. 2 Farmakokinetični podatki
In cattle, the pharmacokinetic profile of tulathromycin when administered as a single subcutaneous dose of 2.5 mg/ kg body weight, was characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Pri govedu je za farmakokinetični profil tulatromicina, vnešenega z enkratnim podkožnim vbrizgavanjem v dozi 2, 5 mg/ ml, značilna hitra in obsežna absorpcija, ki ji sledi hitra razporeditev in počasno izločanje.
The maximum concentration (Cmax) in plasma was approximately 0.5 µg/ ml; this was achieved approximately 30 minutes post-dosing (Tmax).
Najvišja koncentracija (Cmax) v plazmi je okoli 0, 5 µg/ ml, dosežena pa je približno 30 minut po vnosu (Tmax).
There is strong evidence of substantial accumulation of tulathromycin in neutrophils and alveolar macrophages.
V homogenizatu pljučnega tkiva je bil zaznan tulatromicin v bistveno višji koncentraciji kot v plazmi, kar očitno kaže na njegovo obilno kopičenje v nevtrofilcih in alveolarnih makrofagih.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/ 2) of 90 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T½) okoli 90 ur v plazmi.
The volume of distribution at steady-state (Vss) determined after intravenous administration was 11 L/ kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 11 L/ kg.
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/ kg body weight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Pri prašičih je za farmakokinetični profil tulatromicina, vnešenega z enkratnim intramuskularnim vbrizgom v dozi 2, 5 mg/ ml, prav tako značilna hitra in obsežna absorpcija, ki ji sledi hitra razporeditev in počasno izločanje.
The maximum concentration (Cmax) in plasma was approximately 0.6 µg/ ml; this was achieved approximately 30 minutes post-dosing (Tmax).
Najvišji koncentracija (Cmax) v plazmi je okoli 0, 6 µg/ ml, dosežena pa je približno 30 minut po vnosu (Tmax).
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/ 2) of approximately 91 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T½) okoli 91 ur v plazmi.
The volume of distribution at steady-state (Vss) determined after intravenous administration was 13.2 L/ kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 13, 2 L/ kg.
In the absence of incompatibility studies, DRAXXIN must not be mixed with other veterinary medicinal products.
Zaradi pomanjkanja študij kompatibilnosti DRAXXINA ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
In use shelf life:
Rok uporabnosti po prvem odpiranju vsebnika:
28 days
36 mesecev 28 dni
No special precautions for storage.
Za shranjevanje ni posebnih navodil
6.5 Nature and composition of immediate packaging
5 6. 5 Vrsta ovojnine in vsebina
Primary packaging:
Stična ovojnina:
Type 1 glass vial with a fluoropolymer coated chlorobutyl stopper and an aluminium overseal.
steklena viala tipa 1 s klorobutilnim zamaškom prevlečenim s fluoropolimerom in aluminijasto zaporko.
Secondary packaging:
Sekundarna ovojnina:
Cardboard box containing one vial.
kartonska škatlica z eno vialo
Vial sizes:
Velikost stekleničk:
20 ml, 50 ml, 100 ml, 250 ml, and 500 ml Not all vial sizes may be marketed.
Ni nujno, da so v prometu vsa navedena pakiranja.
250 ml and 500 ml vials must not be used for pigs.
250 ml in 500 ml stekleničke se ne smejo uporabljati za zdravljenje prašičev.
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK.
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ Velika Britanija
First authorisation:
11.
11/ 11/ 2003 Renewal:
2003 Podaljšanje:
19/ 09/ 2008
DATUM REVIZIJE BESEDILA
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /
6 PROHIBITION OF SALE, SUPPLY AND/ OR USE
6 DODATEK II
Pfizer PGM Z. I. d’ Amboise F-37530 Pocé-sur-Cisse France
Pfizer PGM Z. I. d’ Amboise F- 37530 Pocé- sur- Cisse Francija
Manufacturing Authorisation issued on 21.06.2001 by Agence Nationale du Médicaments Vétérinaire, France.
2001 s strani Agence Nationale du Médicaments Vétérinaire, Francija.
Tulathromycin is included in Annex I of Council Regulation (EEC) No 2377/ 90 in accordance with the following table:
2377/ 90 v skladu z naslednjo tabelo:
Marker
Marker zaostanek
Target
aktivna snov
Other
vrsta
active substance(s) 1
zaostankov (MRL) Tulatromicin1
residue
(2R, 3S, 4R, 5R, 8R,
species
Govedo
tissues
100 µg/ kg 3000 µg/ kg
provisions
Maščoba
Tulathromycin
Ni za uporabo
(2R, 3S, 4R, 5R, 8R, 10R, Bovine 11R, 12S, 13S, 14R)-2- ethyl-3,4,10,13- tetrahydroxy- 3,5,8,10,12,14-
10R, 11R, 12S, 13S,
Fat Liver Kidney
pri živalih,
Not for use in lactating cattle producing milk for human consumption.
katerih mleko je namenjeno za prehrano ljudi.
hexamethyl-11-[[3,4,6- Porcine trideoxy-3- (dimethylamino)-ß-D- xylohexopyranosyl]oxy]- 1-oxa-6- azacyclopentadecan-15-on, expressed as tulathromycin equivalents
(dimethylamino) - ß- D - xylohexopyranosyl] oxy]
Skin + fat Liver Kidney
Koža + maščoba
1 OJ No.
8 1 OJ No.
L211 of 12.06.2004
2004
9 Annex II of Council Regulation (EEC) No 2377/ 90:
2377/ 90:
Pharmacologically active substance Propylene Glycol2 Monothioglycerol3 Citric Acid4
Farmakološko aktivna snov
Animal Species All food animal species All food animal species All food animal species
Marker zaostanek
Hydrochloric Acid5
Klorovodikova kislina5
All food animal species
Vse vrste za proizvodnjo živil
For use as excipient
Za uporabo kot pomožne snovi
L045 of 15.02.1997 3 OJ No.
2.
L290 of 05.12.1995 4 OJ No.
1997 3 OJ No.
L272 of 25.10.1996 5 OJ No.
L290 of 5.
L143 of 27.06.1995
1995
10 ANNEX III
10.
LABELLING
11 PODATKI NA ZUNANJI OVOJNINI
(20 ml)
20 ml
Tulathromycin Monothioglycerol
tulatromicin monotioglicerol
Treatment and prevention of bacterial and mycoplasmal infections in cattle and pigs.
Zdravljenje in preprečevanje bakterijskih in mikoplazemskih infekcij pri govedu in prašičih.
See package leaflet for complete list of indications, sensitive pathogens and directions for use.
Preberite navodilo za uporabo za celoten seznam indikacij in občutljivih mikroorganizmov.
A single subcutaneous (cattle) or intramuscular (pigs) injection of 2.5 mg tulathromycin/ kg body weight (1 ml/ 40 kg body weight).
Enkratna podkožna (govedo) ali intramuskularna (prašiči) aplikacija 2, 5 mg tulatromicina na 1 kg telesne teže (1ml / 40 kg telesne teže).
Tulathromycin is irritating to eyes and may cause sensitisation by skin contact.
Tulatromicin draži oči in lahko povzroči senzibilizacijo pri kožnem stiku.
Wash hands after use.
Po uporabi je potrebno umiti roke.
Expires < mm/yyyy >
EXP {mesec/ leto}
28 days Discard date:
28 dni
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsak neporabljen zdravilo z uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
For animal treatment only - to be supplied only on veterinary prescription.
Samo za živali - oskrba le na podlagi veterinarskega recepta
< Batch > < Lot >
Serija
15 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
14 PODATKI NA ZUNANJI OVOJNINI
(50 ml)
50 ml
lactating cattle producing milk for human consumption.
Ni dovoljena uporaba pri živalih v laktaciji, katerih mleko je namenjeno prehrani ljudi.
18 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
17 PODATKI NA ZUNANJI OVOJNINI
(100 ml)
100 ml
21 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
20 PODATKI NA ZUNANJI OVOJNINI
(250 ml)
250 ml
DRAXXIN 100 mg/ ml solution for injection for cattle
DRAXXIN 100 mg/ ml raztopina za injiciranje za govedo in prašiče
Cattle
Govedo in prašiči
Treatment and prevention of bacterial and mycoplasmal infections in cattle.
Zdravljenje in preprečevanje bakterijskih in mikoplazemskih infekcij pri govedu in prašičih.
A single subcutaneous (cattle) injection of 2.5 mg tulathromycin/ kg body weight (1 ml/ 40 kg body weight).
Enkratna podkožna (govedo) ali intramuskularna (prašiči) aplikacija 2, 5 mg tulatromicina na 1 kg telesne teže (1ml / 40 kg telesne teže).
24 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
23 PODATKI NA ZUNANJI OVOJNINI
(500 ml)
500 ml
Expires < mm/yyyy >
Načeto zdravilo uporabite do …
28 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
27 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
31 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
30 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
33 PACKAGE LEAFLET DRAXXIN 100 mg/ ml solution for injection for cattle and pigs
32 NAVODILO ZA UPORABO DRAXXIN 100 mg/ ml raztopina za injiciranje za goveda in prašiče
Marketing authorisation holder Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ UK.
Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ Velika Britanija
Manufacturer for the batch release Pfizer PGM Z. I. d’ Amboise F-37530 Pocé-sur-Cisse France
Pfizer PGM Z. I d' Amboise F- 32530 Pocé- sur- Cisse Francija
DRAXXIN 100 mg/ ml solution for injection for cattle and pigs
DRAXXIN 100 mg/ ml raztopina za injiciranje za goveda in prašiče
Cattle Treatment and prevention of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Govedo Zdravljenje in preprečevanje dihalnih obolenj goveda (BRD), povzročenih z Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis občutljivih na tulatromicin.
Pigs Treatment and prevention of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae and Haemophilus parasuis sensitive to tulathromycin.
Prašiči Zdravljenje in preprečevanje dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pastuerella multocida, Mycoplasma hyopneumoniae in Haemophilus parasuis občutljivih na tulatromicin.
Do not use in case of hypersensitivity of the target animals to macrolide antibiotics Do not use the product simultaneously with other macrolides or lincosamides Do not use in lactating cattle producing milk for human consumption Do not use in pregnant cows or heifers, which are intended to produce milk for human consumption, within 2 months of expected parturition
Ne uporabite zdravila pri brejih kravah ali telicah, namenjenih za proizvodnjo mleka za prehrano ljudi, če je do predvidenega poroda manj kot 2 meseca.
Subcutaneous administration of DRAXXIN to cattle frequently causes transient pain reactions and local swellings at the injection site that can persist for up to 30 days.
Pri govedu podkožno vbrizgavanje DRAXXINA pogosto povzroči trenutno bolečino in lokalno oteklino na mestu vbrizgavanja, ki lahko vztraja tudi do 30 dni.
Cattle and pigs
Govedo in prašiči.
Cattle (treatment and prevention) 2.5 mg tulathromycin/ kg body weight (equivalent to 1 ml/ 40 kg body weight).
Govedo Enkratna podkožna aplikacija tulatromicina v odmerku 2, 5 mg/ kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže).
Pigs 2.5 mg tulathromycin/ kg body weight (equivalent to 1 ml/ 40 kg body weight).
Prašiči Enkratna intramuskularna aplikacija tulatromicina v odmerku 2, 5 mg/ kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže) na področje vratu.
To ensure correct dosage body weight should be determined as accurately as possible to avoid underdosing.
Za zagotovitev pravilnega odmerjanja je potrebno čim natančneje določiti telesno težo obolele živali, da zagotovimo zadostno odmerjanje zdravila.
Use within 28 days of first opening or broaching the vial.
Zdravilo porabite v 28 dneh po odprtju stekleničke.
Do not use after the expiry date stated on the label.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na zunanji ovojnini.
If accidental eye exposure occurs, flush the eyes immediately with clean water.
V primeru nenamernega stika očesa z zdravilom, prizadeto oko nemudoma sperite s čisto vodo.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru nenamernega samo- injiciranja zdravila se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
19/ 09/ 2008
MM/ YYYY
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu/
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency, EMEA) http: // www. emea. europa. eu /
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, and Haemophilus parasuis the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulatromicin izkazuje in vitro aktivnost proti Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis ter proti Actinobacillus pleuropneumoniae, Pastuerella multocida, Mycoplasma hyopneumoniae in Haemophilus parasuis to je proti patogenim bakterijam, ki so najpogostejši povzročitelji obolenj dihal pri govedu in prašičih.
37 In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/ kg body weight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
36 Pri prašičih je za farmakokinetični profil tulatromicina, vnešenega z enkratnim intramuskularnim vbrizgom v dozi 2, 5 mg/ ml, prav tako značilna hitra in obsežna absorpcija, ki ji sledi hitra razporeditev in počasno izločanje.
250 ml and 500 ml vials must not be used for pigs.
250 ml in 500 ml viale se ne smejo uporabljati za zdravljenje prašičev.
Suomi/ Finland Pfizer Oy Animal Health, Puh/ Tel: +358 (0)9 4300 40
Suomi/ Finland Pfizer Oy Animal Health, Tel: +358 (0) 9 4300 40
What is Duvaxyn WNV?
Kaj je zdravilo Duvaxyn WNV?
Duvaxyn WNV is a vaccine containing an inactivated West Nile virus (inactivated means that the virus has been killed so that it cannot cause the disease any more).
Zdravilo Duvaxyn WNV je cepivo, ki vsebuje inaktivirani virus West Nile (inaktiviran pomeni, da je bil virus uničen, zaradi česar ne more več povzročiti bolezni).
What is Duvaxyn WNV used for?
Za kaj se zdravilo Duvaxyn WNV uporablja?
Duvaxyn WNV is a vaccine used in horses to protect against West Nile virus disease.
Duvaxyn WNV je cepivo, ki se uporablja pri konjih za zaščito proti bolezni, ki jo povzroča virus West Nile.
The vaccine reduces the number of viraemic horses (these are horses with virus circulating in their blood stream) The vaccine is injected intramuscularly (into a muscle) in the neck of the horse.
Cepivo zmanjšuje število viremičnih konjev (konjev, pri katerih virus kroži v krvnem obtoku). Cepivo se injicira intramuskularno (v mišico) na področje vratu konja.
How does Duvaxyn WNV work?
Kako zdravilo Duvaxyn WNV deluje?
Duvaxyn WNV is a vaccine.
Duvaxyn WNV je cepivo.
When it is given to horses, the animal’ s immune system (their natural defence mechanism) learns how to make antibodies (a special type of protein) to fight the disease.
Ko ga konji prejmejo, se imunski sistem živali (njihov naravni obrambni mehanizem) nauči tvoriti protitelesa (posebno vrsto beljakovine) za boj proti bolezni.
In the future, if the horses are exposed to the West Nile virus, the immune system will be able to make those antibodies quicker and this will help them fight the disease.
Če bodo konji v prihodnosti izpostavljene virusu West Nile, bo njihov imunski sistem ta protitelesa tvoril hitreje, kar jim bo pomagalo v boju proti bolezni.
How has Duvaxyn WNV been studied?
Kako je bilo zdravilo Duvaxyn WNV raziskano?
The company carried out laboratory safety studies in both young foals (6 months of age) and pregnant mares using the vaccine.
Družba je opravila laboratorijske študije varnosti z uporabo cepiva na mladih žrebetih (starih 6 mesecev) in brejih kobilah.
These showed the safety of the use of the vaccine in horses in general and in young (6 months of age or older) and pregnant animals in particular.
Te so pokazale varnost uporabe cepiva pri konjih na splošno ter zlasti pri mladičih (starih 6 mesecev ali več) in brejih živalih.
They then performed a number of field trials which further confirmed the safety of Duvaxyn WNV and proved its efficacy in reducing the number of viraemic horses and thereby protecting against the disease.
Nato so opravili številne študije na terenu, ki so dodatno potrdile varnost cepiva Duvaxyn WNV in dokazale njegovo učinkovitost pri zmanjševanju števila viremičnih konjev ter s tem zaščiti proti bolezni.
What benefit has Duvaxyn WNV shown during the studies?
Kakšne koristi je zdravilo Duvaxyn WNV izkazalo med študijami?